Patents by Inventor Susan Erickson-Viitanen

Susan Erickson-Viitanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11896717
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: February 13, 2024
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20230136579
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: December 29, 2022
    Publication date: May 4, 2023
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11576864
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: February 14, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11576865
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: February 14, 2023
    Assignees: Incyte Corporation, Incyte Holdings Comoration
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20220331253
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 20, 2022
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20220323363
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20220211631
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: March 23, 2022
    Publication date: July 7, 2022
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11337927
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 24, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20210128477
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 6, 2021
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 10874616
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 29, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20190231696
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: November 14, 2018
    Publication date: August 1, 2019
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 10166191
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: January 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
    Publication number: 20140135350
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 15, 2014
    Applicant: Incyte Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
  • COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION
    Publication number: 20080108586
    Abstract: The present invention is directed to combination therapies for treatment of Human Immunodeficiency Virus (HIV) infection comprising administration of a CCR5 antagonist in combination with other therapeutic agents.
    Type: Application
    Filed: September 5, 2007
    Publication date: May 8, 2008
    Applicant: Incyte Corporation
    Inventors: Paul Friedman, Susan Erickson-Viitanen